Drug Trial Radar · NCT05349617
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
413
Actual
Start
May 12, 2022
Primary completion
Jun 19, 2023
Study completion Aug 8, 2023
Sponsor
- Lead sponsor
- Bavarian NordicIndustry
- Sponsor type
- Industry
- Collaborators
- Emergent BioSolutions
- First posted
- Apr 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
Conditions
- Chikungunya Virus
Interventions
CHIKV VLP/adjuvantBiological
PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant
PlaceboBiological
Placebo is comprised of formulation buffer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anti-CHIKV SNA Titer (NT80) Seroresponse Rates at Day 22 in Baseline Seronegative ParticipantsTime frame: 21 days postvaccination
- Anti-CHIKV SNA Titer (NT80) Geometric Mean Titers (GMT) at Day 22Time frame: 21 days postvaccination
- Incidence of Solicited Adverse Events (AE)Time frame: 7 days postvaccination
- Incidence of Unsolicited AEsTime frame: 28 days postvaccination
- Incidence of Serious Adverse Events (SAE)Time frame: 182 days postvaccination
- Incidence of Medically Attended Adverse Events (MAAE)Time frame: 182 days postvaccination
- Incidence of Adverse Events of Special Interest (AESI)Time frame: 182 days postvaccination
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Suncoast Research Associates, LLC
Miami, Florida
Panax Clinical Research
Miami Lakes, Florida
Global Clinical Research Professionals (GCP)
St. Petersburg, Florida
AMR Kansas City
Kansas City, Missouri
Rochester Clinical Research, Inc.
Rochester, New York
Coastal Carolina Research Center
North Charleston, South Carolina
DM Clinical Research CyFair
Houston, Texas
BHFC Research
San Antonio, Texas
DM Clinical Research Tomball
Tomball, Texas
Spaulding Clinical
West Bend, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.